Sockalingam: Under 20% of Private Plans Cover Obesity Drugs

Fewer than 20 per cent of Canadians with private drug benefit plans currently have access to Health Canada-approved obesity treatment medications, according to commentary published by Obesity Canada in the wake of Health Canada's generic semaglutide authorizations [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/].

Coverage gap framed against G7-first approvals

The commentary, written by Dr. Sanjeev Sockalingam, Scientific Director of Obesity Canada, was published as Health Canada confirmed Canada is the first G7 country to authorize a generic version of semaglutide [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/]. The first authorization, granted to Dr. Reddy's Laboratories, was announced by Health Canada on April 28, 2026 as a generic of the brand-name drug Ozempic [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html]. A second authorization, for Apotex, was issued on May 1, 2026, with seven other generic semaglutide submissions still under review [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html].

$27.6 billion price tag on untreated obesity

Sockalingam's commentary cites estimates that untreated obesity cost Canada $27.6 billion in 2023, including direct healthcare costs and broader productivity losses [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/]. He argues that those costs are already being absorbed by the system, and that the policy choice now facing governments, insurers and employers is whether to continue paying for untreated obesity or to invest in care that could prevent complications over time [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/].

Generic approvals reframe the coverage debate

According to the commentary, lower-cost Health Canada-approved options may help reduce one of the most persistent barriers in obesity care, and should prompt governments, insurers and employers to reconsider how obesity treatment is covered [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/]. Sockalingam writes that affordability should not depend on whether a patient can find a lower-cost product, and that Canadians should not have to pay out of pocket for evidence-based treatment of a chronic disease when similar pathways are covered for conditions such as diabetes, hypertension, arthritis or heart disease [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/].

Regulatory status of the products in question

Health Canada states that the generic semaglutide injections authorized to date are indicated for the once-weekly treatment of adult patients with type 2 diabetes to manage blood sugar levels, the same indication as the existing brand-name product [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html]. Both authorizations followed reviews against Health Canada's criteria for safety, efficacy and quality for generic drugs [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html].

Pricing context on GLP1Prices.ca

Brand-name GLP-1 list prices remain elevated across Canadian pharmacies tracked by GLP1Prices.ca. Current verified ranges include:

• Ozempic: CAD $222 to $663
• Wegovy: CAD $270 to $490
• Rybelsus: CAD $230 to $293.99
• Mounjaro: CAD $283.08 to $813
• Zepbound: CAD $276 to $609

Readers tracking the rollout of authorized generic semaglutide products can monitor regulatory progress through our generic semaglutide tracker, review private and public plan questions on the insurance coverage checker, or consult the FAQ for general background.

What Obesity Canada is and isn't saying

The commentary is explicit that Obesity Canada does not endorse specific medications, brands or manufacturers, and that pharmacotherapy should only be considered after a full clinical assessment by a healthcare professional competent in evidence-based obesity care [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/]. Sockalingam writes that medication can be one tool among several, alongside behavioural and psychological support and metabolic and bariatric surgery, depending on the person's needs and goals [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/].

This article is for informational purposes only and does not constitute medical advice.